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The question on the relative infectuousness of asymptomatic and symptomatic infections of COVID-19 is 
surrounded by contradictory clinical findings and confusion. This article undertakes a critical review of the 
available clinical literature on this topic, from the perspective of individual infection cycles and from the 
perpective of epidemiologic dynamics. Using the available results from the clinical and virological literature, 
we analyse how they fit in the time table of individual infection cycles, separately for the symptomatic and 
asymptomatic infection mode. The time table is based on a Susceptible-Infected-Resolve (SIR) mainframe, 
but the Infection compartment is sub-divided in 5 clinical stages for the symptomatic infection mode and 3 
clinical stages for the asymptomatic infection mode. From the perpective of epidemiologic dynamics, the 
only period that matters is the time interval that infectives shed viable virus material, which is capable of 
self-replication in another host. The duration of this period can only be assessed by subjecting the positive 
RT-PCR tests samples to viral culture to isolate virus material that is able to self-replicate. Doing this on a 
daily basis reveals the time profile of effective infectuousness, separately for symptomatics and 
asymptomatics. For mild to moderate symptomatic cases we calculate that this period is 14 days on average, 
while for asymptomatic cases it is 9 days. Most of the replication-competent virus material is emitted during 
the first 4 days of this period, with few differences between symptomatics and asymptomatics. Because they 
shed virus over a longer interval, symptomatic infectives are likely to constitute the largest source of 
secondary infections. However, asymptomatic infectives have the largest average daily infectivity, because 
they shed most infective virus load during a short period. If the contact network of susceptibles has a 
sufficiently high share of asymptomatics in their early infection stage, the asymptomatic persons become the 





pandemic	 is	 characterised	 by	 two	different	 infection	modes,	 a	 symptomatic	 and	 an	
asymptomatic	one.	 In	 the	 latter	case,	persons	get	 infected	without	experiencing	any	
symptoms,	and	during	their	unmitigated	interaction	they	may	disseminate	the	virus	to	
other	people.	On	top	of	that,	the	symptomatic	infection	mode	has	a	pre-symptomatic	
stage	 during	 which	 the	 infected	 person,	 without	 knowing	 it,	 is	 already	 capable	 of	
transmitting	 the	 virus	 to	 others.	 Persons	without	 symptoms	 tend	 to	move	 freely	 in	
society	 and	 interact	 with	 non-infected	 people	[8,70,79,35].	 Symptomless	 infection	
transmission	provides	the	virus	with	a	distinct	evolutionary	advantage	that	allowed	it	
to	develop	COVID-19	into	a	worldwide	pandemic.	The	present	paper	proposes	a	new	






and	 the	 United	 Kingdom	 [76]	 found	 that	 32-33	 percent	 of	 the	 persons	 who	 tested	
positive,	 reported	 to	 have	 had	 no	 symptoms.	 Reducing	 the	 number	 of	 undetected	
asymptomatic	 infections	would	 requires	mass	 testing	 of	 people	without	 symptoms.	
This	is	only	applied	in	a	few	regions	and	countries	(e.g.	China,	Singapore).	In	the	early	
stages	 of	 the	 current	 pandemic	many	 countries	 had	 a	 lack	 of	 testing	material,	 and	
national	CDCs	targeted	all	testing	activity	at	symptomatic	infectives	and	their	contacts.		













Since	 the	 second	 half	 of	 2020,	 the	 increase	 in	 testing	 activity	 yielded	 a	 stream	 of	




of	 the	COVID-19	virus,	partly	due	 to	 contradictory	empirical	 findings.	 In	The	BMJ	 of	
December	2020,	Pollock	and	Lancaster	[58]	concluded:	"The	relations	between	viral	load,	
viral	 shedding,	 infectiousness,	 and	 duration	 of	 infectuousness	 are	 not	 well	 understood".		
Similarly,	in	April	2021,	McEvoy	et	al.	[46]	concluded	in	BMJ	Open	that:	"Overall,	there	is	
currently	 only	 a	 limited	 number	 of	 published	 studies	 from	 which	 it	 is	 possible	 to	 derive	 a	
quantitative	estimate	of	the	relative	infectiousness	of	asymptomatics.	[..].	There	is	considerable	
heterogeneity	 in	 estimates	 of	 relative	 infectiousness	 highlighting	 the	 need	 for	 further	
investigation	 of	 this	 important	 parameter".	 In	May	 2021,	 Chen	 et	 al.	[16]	 state	 that	 "data	




table	 of	 individual	 infection	 cycles,	 and	 on	 recent	 research	 advances	 regarding	 the	
quantity	of	virus-shedding	activity,	and	regarding	the	time	pattern	of	the	emitted	virus	





each	 with	 linearly-related	 stages.	 The	 third	 section	 provides	 a	 stylised	 empirical	
version	 of	 this	 time	 table,	 building	 on	 clinical	 studies	 and	 meta	 analyses	 on	 the	
differences	of	infection	modes,	virus	shedding,	virus	loads,	and	on	the	self-replication	
quality	of	the	 latter.	This	yields	a	stylised	 'average'	 time	path	of	 individual	 infection	
cycles.	 The	 clinical	 sources	 are	 documented	 in	 two	 separate	 annexes.	 For	
symptomatics,	we	focus	on	the	mild	and	moderate	cases,	because	the	severest	cases	
are	generally	hospitalised	and,	 from	the	perspective	of	epidemic	dynamics,	 isolated.	
The	 fourth	 section	 proposes	 a	 rigorous	 quantitative	 definition	 of	 the	 relative	
infectuousness	 of	 the	 asymptomatic	 and	 symptomatic	 infection	 modes,	 further	




The	 analytical	 set-up	 follows	 the	 Susceptible-Infected-Resolved	 model	 with	 two	
parallel	 infection	 modes	 (symptomatic,	 asymptomatic)	 for	 the	 "Infected"	 compart-
ment.	Moreover,	the	"Infected"	compartment	is	sub-divided	in	sequential	sub-periods	
that	 differ	 by	 infection	 mode.	 The	 first	 column	 demarcates	 the	 jumps	 or	 switches	
between	 the	 main	 epidemic	 state	 variables	 (Susceptible,	 Infected,	 Resolved).	 The	

























































































is	 therefore	 the	 end	 of	 the	 effective	 transmission	 period	 from	 an	 epidemiological	





The	 presence	 of	 the	 asymptomatic	 infection	 mode	 can	 be	 assessed	 objectively	 by	
testing	 for	 emitting	 of	 virus	 RNA	 (RT-PCR	 test)	 or	 for	 the	 presence	 of	 antibodies	
(serological	 test).	 However,	 the	 asymptomatic	 person	 experiences	 and	 reports	 no	




the	 asymptomatic	person	 is	 capable	of	 transmitting	 the	disease	 to	 susceptibles	 and	
often	mixes	 freely	with	susceptibles.	Stage	2	ends	when	 the	 infect	person	no	 longer	
sheds	virus	material	that	has	the	quality	to	self-replicate	in	another	host	(event	𝑢$).	










Note	 that	Table	1	does	not	distinguish	specific	sub-intervals	 for	 time	spent	 in	home	
quarantaine,	 hospital	 treatment,	 or	 ICU	 treatment.	While	 this	 can	 be	 important	 for	











The	 stylised	 time-table	 of	 the	 individual	 infection	 cycles	 is	 based	 on	 the	 empirical	
evidence	from	a	broad	clinical	and	epidemiological	literature.	Annex	I	provides	details	
on	 the	 distribution	 of	 the	 duration	 variable	 in	 the	 original	 source	 material	 (95%	
confidence	intervals,	inter-quartile	range,	standard	deviation).	
The	gains	of	the	simplifications	occur	in	terms	of	the	tractability	and	controllability	of	







selected	 threshold	 value.	 The	 results	 for	 symptomatic	 infectives	 do	 not	 show	 a	
consistent	picture,	given	the	relation	between	different	clinicals	intervals.	The	results	








































	 	 	 	 	 	
v	to	(𝑟"	-	1)									$)	 21.8	 ..	 ..	 ..	 7.6	 S.	Korea,	[37]	
m	to	(𝑟"	-	1)						&)	 25.2	 ..	 ..	 ..	 4.9	 S.	Korea,	[52]	
m	to	(𝑟"	-	1)						&)	 ..	 18.0	 15.0	a)	 22.0	a)	 ..	 S.	Korea,	n=328,	[73]	
p	to	(𝑟"	-	1)							@)	 17.0	 ..	 15.5	 18.6	 ..	 meta	study	[12]	
Asymptomatics	 	 	 	 	 	
	
m	to	(𝑢$	-	1)						%)	 ..	 9.5	 7.0	a)	 14.0	a)	 ..	
S.	Korea,	m	to	first	negative	
PCR	test,	n=68,	[73]	
m	to	(𝑟$	-	1)						%)	 ..	 14.5	 11.0	a)	 21.0	a)	 ..	
S.	Korea,	m	to	full	negative	
conversion,	n=68,	[73]	
p	to	(𝑟$	-	1)								§)	 	 12.8	 	 	 	 US	CDC,		[10],	this	section	
p	to	(𝑟$	-	1)								§)	 19.1	 ..	 ..	 ..	 7.5	 S.	Korea,	[37]	







measurement	 impact	 from	 testing	 itself	 [8,4,12,7,53,70,26].	 Moreover,	 for	 a	 consistent	
interpretation	we	build	on	a	formal	model	that	is	separately	presented	in	Annex	I.	Here	
we	describe	the	procedure	stepwise	by	evaluating	the	relevant	empirical	findings.		
Virus	 shedding	 by	 symptomatics.	 A	 high	 nasopharyngeal	 viral	 load	 in	 RT-PCR	 tests	
increases	the	probability	of	secondary	infections	[29].	For	symptomatics,	the	viral	loads	












was	 found	 even	 later.[53,54,77]	 Also	 immunocompromised	 patients	may	 emit	 culture-
positive	 virus	 material	 for	 a	 longer	 period.[55,75]	 A	 different	 detection	 method[65,38]	
based	 on	 subgenomic	 RNA,	 also	 found	 rare	 cases	 of	 persistent	 active	 virus	 beyond	
v+10.	Severe	cases	are	in	most	countries	hospitalised	and	isolated,	thus	reducing	their	
impact	 on	 overall	 infection	 dynamics.	 Walsh	 et	 al.	 draw	 the	 following	 qualified	





infectuousness	 over	 time	may	 be	 quantified	 using	 the	 time	 profile	 for	 successfully	
recovered	 replication-competent	 viruses	 from	 positive	 RT-PCR	 nasopharyngeal	
specimens.	A	large	US	cohort	study	[54]	reports	a	time	profile	of	virus-recovery	success	
rates	from	daily	positive	PCR	samples.	The	study	itself	presents	the	profile	relative	to	
event	 v	 (onset	 of	 symptoms),	 but	 for	 comparability	 with	 asymptomatics,	 who	 by	
definition	 have	 no	 symptoms,	we	 transpose	 the	 profile	 to	 a	 common	 event	 in	 both	
infection	modes,	namely	event	p	(infective	acquires	capability	to	transmit	the	virus).	
Clinical	evidence	summarised	in	Annex	Table	A2	finds	that	there	are	on	average	4	days	





• interval		(p+14)	-	(𝑟" − 1)	:		0%			of	specimens		with	viable	virus	
The	first	interval	is	the	presymptomatic	phase,	which	turns	out	to	be	the	most	infective	
sub-period.[24]	 Using	 the	 virus-recovery	 results	 of	 the	 third	 time	 interval	 as	 the	
reference	point,	the	comparative	infectuousness	of	the	first	interval	is:	71/30 ≈ 2.37.	
Doing	the	same	for	all	sub-periods,	gives	the	daily	infectuousness	weights	for	the	four	









Virus	 shedding	 by	 asymptomatics.	 In	 March	 2021,	 the	 US	 CDC[10]	 published	 the	
modelling	 assumptions	 for	 their	 latest	 epidemic	 planning	 scenarios	 for	 COVID-19.	
 10 























8	and	11	days.	Also	 for	asymptomatics	 there	are	 long-shedding	outlayers.	 Immuno-
depressed,	severely	ill	patients	with	other	diseases	than	COVID-19	and	infected	by	the	
asymptomatic	COVID-19	 infection	mode,	display	 shedding	of	 active	 virus	 for	 a	 long	
time,	even	up	to	70	days.[2]	Due	to	their	non-COVID-19	illness,	such	cases	tend	to	occur	






time	pattern	 for	symptomatic	 infectives,	 the	three	sub-periods	with	culture-positive	
virus	shedding	are	reduced	with,	respectively,	1,	2	and	2	days	for	asymptomatics:	
• interval:			(p)	—	(p+2)														:	71%	of	specimens		(𝑐. 𝑖. =	2.37)	
• interval:			(p+3)	—	(p+5)									:	47%	of	specimens		(𝑐. 𝑖. =	1.57)	
• interval:			(p+6)	—	(p+8)									:	30%	of	specimens		(𝑐. 𝑖. =	1.0)	








the	 symptomatics.	However,	 the	 average	 daily	 infectivity	 for	 asymptomatics	 during	
their	 9	 days	 with	 shedding	 active	 virus	 material	 is	 1.65,	 which	 is	 higher	 than	 for	



























Quantifying	 `average'	duration	 is	not	 equally	different	 for	 all	 stages	of	 the	 infection	
process.	 The	 virological	 research	 results	 with	 regard	 to	 the	 duration	 of	 stage	4	









The	effective	 infection	 cycle	 for	 symptomatics	 (stages	2-3-4)	ends	at	 event	us	and	 it	
lasts	on	average	14	days	for	mild	and	moderate	cases.	In	the	first	half	of	this	interval	
(7	days),	 the	 infected	 individual	 is	non-tested,	non-isolated	and	non-treated.	This	 is	
followed	by	a	period	of	again	7	days,	during	which	the	person	is	confirmed,	treated	and	
has	some	form	of	isolation.	The	effective	infection	cycle	for	asymptomatics	(stage	2)	
lasts	 on	 average	 9	 days.	Most	 often,	 this	 full	 period	 is	without	 testing,	 isolation	 or	
treatment.	 An	 important	 result	 is	 also	 that	 the	 average	 daily	 infectuousness	 of	
asymptomatics	 is	 rather	 higher	 than	 lower,	 compared	 to	 symptomatics.	 The	 result	
corroborates	some	empirical	findings.[25,83]	
4.		Relative	infectuousness	and	epidemiological	consequences	
We	 searched	 the	 literature	 for	 a	 clear-cut,	 operational	 definition	 of	 the	 relative	
infectuousness	concept,	but	we	did	not	find	a	generally	accepted	methodology.[dx,	ea,	eb]	
Most	 of	 the	 literature	 agrees	 that	 virus-shedding	 activity	matters,	 and	 that	 also	 the	
quality	of	 the	virus	matters,	but	 that	 is	where	 the	agreement	stops.	Here	we	define	
relative	infectuousness	as	the	product	of		(i)	the	mean	number	of		virus-shedding	days	
per	 infective,	 (ii)	 daily	 	 recovery	 rate	 of	 active,	 replicable	 virus	 material,	 and	 if	
applicable,	 (iii)	downward	mitigation	of	 contacts	with	susceptibles	 through	medical	
isolation	or	self-isolation.		
The	 third	 element	 is	 added	 for	 symptomatics	 in	 particular.	 After	 confirmation,	 the	
latter	enter	stage	4	of	their	individual	infection	cycle	(Table	3).	It	is	plausible	to	assume	
that	the	frequency	and	intensity	of	their	individual	contacts	with	susceptibles	will	be	
reduced	 in	 this	 stage.	While	 studies	 are	 available	 that	 quantify	 the	 generic	 contact-
reducing	effects	of	public-health	policies,	we	did	not	find	any	study	that	quantifies	the	
individual	contact-reducing	effects	of	being	confirmed	as	a	COVID-19	infective.	We	will	







preceding	section).	The	next	effect	 is	 that	also	 the	average	daily	 infectivity	over	 the	




has	much	 less	 relevance.	 If	 asymptomatic	 infections	 are	 identified	 through	 contact-
tracing	 or	 community-wide	 PCR	 testing,	 it	 is	 likely	 that	 some	 form	 of	 isolation	 is	
strongly	 advised	 or	 imposed.	 Best	 estimates[7,4,10,8,48,35,37,70,53]	of	 the	 share	 of	
asymptomatics	vary	between	15%	and	67%	of	total	infections,	while	only	tiny	numbers	
of	asymptomatic	infections	are	indeed	identified.	The	effect	of	isolation	after	detection	










and	 50	 'standard'	 symptomatics.	 All	 infectives	 are	 of	 the	 same	 infection	 cohort	𝜃.	
Figure	1	shows	that	the	susceptibles	in	the	first	three	days	have	an	equal	probability	of	
contracting	the	disease	from	an	asymptomatic	or	symptomatic	person.	From	day	p+3	







'standard	 infection	 days'	 per	 individual	 infection	 cycle,	 as	 defined	 in	 section	3:	 for	
unmitigated	 symptomatics	 it	 is	 22.33;	 for	 symptomatics	 with	 medically-induced	
isolation	it	is	17.14,	and	for	asymptomatics	it	is	14.80.		Hence,	if	all	circumstances	are	
the	 same,	 there	 is	 a	 higher	 probability	 of	 contracting	 the	 COVID-19	 virus	 from	 a	
symptomatic.	The	main	reason	is	 that	symptomatics	shed	active	virus	over	a	 longer	
period.	 A	 second	 reason	 could	 be	 the	 phenomenon	 of	 super	 spreaders	 (severe	
symptomatic	 cases	 with	 large	 loads	 of	 viable	 virus	 and	 many	 contacts)	 who	 may	
generate	 a	 disproportionally	 larger	 infection	 risk.	 So	 far,	we	did	 not	 find	 any	 peer-
reviewed	 empirical	 report	 that	 documents	 similar	 super	 spreaders	 among	
asymptomatics.[62,80]		
The	 susceptible's	 actual	 probability	 of	 contracting	 COVID-19	 from	 either	 infection	
mode	depends	not	only	on	their	relative	infectuousness,	but	also	on	the	composition	of	




susceptible's	 network.	 The	 shift	 occurs	 when	 66%	 of	 the	 contacts	 group	 of	 the	
susceptible	are	asymptomatics.	We	corrected	for	the	length	of	the	infective	cycle.		
	
This	 paper	 did	 not	 control	 for	 the	 external	 factors	 that	 may	 affect	 relative	
infectuousness	at	the	individual	level:	virus	mutations	(RI	could	differ	by	virus	variant),	
heterogeneity	of	susceptibles	(age,	overall	health,	physical	condition),	and	vaccination	
profiles.	 There	 is	 evidence[e.g.	 19,23,7]	 that	 susceptibles	 with	 particular	 characteristics	
Share (%) of asymptomatic infectives in contacts network 
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(age,	 physical	 condition,	 non-obese)	 are	 more	 likely	 than	 other	 susceptibles	 to	 be	
infected	with	an	asymptomatic	variant	or	a	mild	symptomatic	variant.	
5.	Discussion	of	the	results	
The	 analytical	 time	 table	 of	 the	 individual	 infection	 cycles	 could	provide	 important	
inputs	 for	 public	 health	 policies	 and	 for	 epidemiologic	 research.	 The	 methodology	
proposed	 in	 this	 paper	 can	 be	 adapted	 for	 use	 in	 case	 of	 other	 bacterial	 or	 viral	
infections	that	are	characterised	by	partly	symptomless	transmission.	It	could	answer	
several	of	 the	 four	key	questions	that	were	quoted	 from	the	recent	 literature	 in	 the	
introductory	section:	
• the	 relations	 between	 viral	 load,	 viral	 shedding,	 infectiousness,	 and	 duration	 of	
infectuousness	 are	now	 framed	 in	 a	 consistent	 framework	 that	may	unify	much	
empirical	and	clinical	work;	
• the	 paper	 provides	 a	 quantitative	 estimate	 of	 the	 relative	 infectiousness	 of	
asymptomatics.	
• Many	 confusing	 and	 apparently	 contradictory	 finding	 on	 virus-shedding	 and	
infectuousness	 in	 earlier	 studies	 can	 now	 be	 interpreted.	 Early	 papers	 often	
described	a	cross-section	of	infected	persons	in	different	stages	of	their	individual	
infection	 cycles.	 It	 is	 only	 logical	 that	 such	 mixing	 up	 results	 in	 contradictory	
findings.	By	controlling	for	the	stage	of	the	 individual	 infection	cycle,	 it	becomes	
possible	 to	 interpret	 apparently	 contradictory	 and	 controversial	 findings	 and	
measurement	 in	 a	 single	 framework.	 We	 propose	 to	 treat	 infection	 data	 as	










Our	 results,	 when	 found	 to	 be	 correct	 in	 further	 clinical	 research,	 should	 have	
consequences	for	the	modelling	of	the	epidemic.	Most	SIR/SEIR/SIRD	models	assume	
that	 the	 time	 during	 which	 individuals	 remain	 infectuous	 can	 be	 described	 by	 an	
exponential	function	and	a	single	̀ exit	rate'	(𝛾)	.	This	is	biologically	unrealistic,	because	
it	implies	that	the	chance	of	recovery	in	a	given	time	interval	is	independent	of	the	time	
since	 infection.	 This	 leads	 to	 the	 distribution	 of	 infectuous	 periods	 being	 overly	
dispersed,	whereas	 in	 fact	 they	are	often	closely	centred	around	the	mean	 infection	
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duration.[43]	 Non-exponential	 distributions	make	 it	 necessary	 that	 the	model	 keeps	
track	of	the	time	since	infection.	If	the	shedding	of	viable	virus	material	indeed	follows	
the	time	profiles	that	we	have	constructed	from	the	empirical	material,	then	it	is	clear	





moderate	 infections,	 can	 on	 average	 transmit	 the	 infection	 during	 14	 days.	 Most	
secondary	transmissions	occur	in	the	first	7	days	when	the	infectives	are	not	isolated,	







We	propose	 to	 calculate	 the	 relative	 infectuousness	of	 both	 infection	modes	by	 the	
number	 of	 	 'standard	 infection	 days'.	 Symptomatic	 infectives	 have	 the	 largest	 total	
number	of		'standard	infection	days'	and	thus	are	likely	to	constitute	the	largest	source	
of	secondary	infections.	However,	we	also	find	that	asymptomatic	infectives	have	the	
largest	 average	 daily	 infectivity;	 they	 shed	most	 infective	 virus	 load	 during	 a	 short	
period.	 This	 means	 that	 if	 the	 share	 of	 asymptomatics	 in	 the	 contact	 network	 of	
susceptibles	 is	 large	 enough	 (>66%),	 they	 may	 become	 the	 dominant	 source	 of	













































































[27]	 	 Jefferson	T.,	E.	 Spencer,	L.	Brassey,	C.	Heneghan	 (2020),	Viral	 cultures	 for	COVID-19	 infectious	









































































































































































phases.	 This	 annex	 describes	 our	 proposed	 indicator,	 using	 the	 infection	 stages	 as		
defined	in	Table	1.	Let	𝑦		be	the	number	of	days	that	an	infected	individual	sheds	virus	
material:	
𝑦' = 𝑟' − 𝑝																																																																																																																																(A1)	





precisely.	 This	 can	 be	 done	 in	 track	 and	 trace	 settings	 to	 find	 secondary	 infectives	
linked	 to	well-traced	primary	 infectives.[e.g.	37,	35,	 23]	 Subject	 the	positive	PCR	samples	
subsequently	to	viral	culture[e.g.	77,29,27]	for	recovering	RNA	material	that	is	still	capable	
of	self-replicating	in	other	hosts.	Register	the	number	of	successful	and	non-successful	







ω"< = Ω"< Ω",8=9:⁄ 							𝑤𝑖𝑡ℎ	𝑡 ∈ 𝑝, . . , (𝑢" − 1)																																																											(A3)	




material	is	no	longer	capable	of	infecting	others,	so	that	𝜔"< = 0		if		𝑡 ≥ (𝑢" − 1)		and	
𝜔$< = 0		if		𝑡 ≥ (𝑢$ − 1).		
The	 infectuousness	 weights	ω<	 can	 be	 used	 to	 obtain	 two	 important	 quantitative	
measures	 for	 individual	 infection	 cycles:	 aggregate	 infectuousness	 (Υ)	 and	 average	
daily	infectuousness	(𝜑K).		
For	most	 symptomatic	 individuals,	 the	 virus-shedding	 period	 splits	 into	 two	 parts,	
before	 and	 after	 medical	 confirmation	 (event	m).	 Before	m,	 the	 symptomatics	 mix	
relatively	free	with	susceptibles	thereby	causing	secondary	infections.	After	m,	most	
 22 
symptomatics	 are	 likely	 to	 apply	 some	 form	 of	 self-isolation	 or	 are	 subjected	 to	
imposed	 medical	 isolation.	 This	 individual	 isolation	 effect	 lowers	 their	 daily	
infectuousness	 weights	 by	 a	 factor	 0 ≤ ℎ< ≤ 1.	 The	 aggregate	 infectuousness	 (Υ)	

















(𝑢" − 1) − p	Υ"																																																																																																																						(𝐴7)	
𝜑'8888 = 	
1
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θ	to	(v-1)	 5.8	 	 5.0	 6.7	 	 Meta-study	[45]	
θ	to	(v-1)	 5.99	 	 4.97	 7.14	 	 SGP,	[71]	
θ	to	(v-1)	 6	 4	-	5	 0	 14	 	 USA,	CDC	[10]	
θ	to	(v-1)	 6.7	 6	 3	 9	 	
CHN,	SGP,	Japan	
[44]	
θ	to	(v-1)	 6.4	 	 5.6	 7.7	 1.7-3.7	 CHN,	Wuhan	[3]	
θ	to	(v-1)	 6.6	 	 0.7	 19	 	
Lombardy,	Italy	
(ITA),	n=5830	[11]	
θ	to	(v-1)	 7.2	 	 	 	 	
serial	interval,	ITA,	
Vo',	n=2850,	[35]	
θ	to	(v-1)	 7.5	 	 5.3	 19	 	
CHN,	Wuhan,	n=12	
[40]	
θ	to	(v-1)	 8.68	 	 7.72	 9.7	 	 CHN,	Tianjin,	[71]	
Chosen	interval	
parameter	value		
























p	to	(v-1)	 ..	 2	 1	 5	 ..	 Ahui,	CHN,	[41]	
p	to	(v-1)	 4.0	 ..	 ..	 ..	 ..	 Utah,	USA,	[38]	
p	to	(v-1)	 4.0	 ..	 ..	 ..	 ..	 SGP,	[71]	
p	to	(v-1)	 5.0	 ..	 ..	 ..	 ..	 Tianjin	,CHN,	[71]	
Chosen	interval	
parameter	value		






































p	to	(m-1)	 ..	 6	 5	 7	
..	 cross-section	of	
countries,	[20]	

































v	to	(m-1)	 4	 ..	 3	 9	 ..	 SGP,	n=17,	[59]	













v	to	(m-1)	 2.9	 ..	 ..	 ..	 2.1	 CHN	[33]	





























m	to	(𝑟"	-	1)	 	 7	 2	 60	 	 USA,	n=111721,	[21]	
m	to	(𝑟"	-	1)	 	 8	 2	 60	 	
USA,	resolve:	death,	
[21]	
m	to	(𝑟"	-	1)	 11.2	 	 8.0	 17.3	 	
CHN,	resolve=	death,	
[66]	
m	to	(𝑟"	-	1)	 12.0	 12.8	 10	 14	 	 CHN,	[22]	
m	to	(𝑟"	-	1)	 	 14	 6	a)	 26	a)	 	
Sweden,	resolve=	
discharge	[69]	
m	to	(𝑟"	-	1)	 	 13	b)	 6	a)	 25	a)	 	
Sweden,	resolve=	
death,		[69]	b)	
m	to	(𝑟"	-	1)	 17.8	 	 16.9	 19.2	 	 resolve=	death		[74]	
m	to	(𝑟"	-	1)	 	 18.0	 15.0a)	 22.0	a)	 	 S.	Korea,	n=328,	[73]	
m	to	(𝑟"	-	1)	 18	 	 13	a)	 25	a)	 	
CHN,	resolve=	hosp.	
discharge,	[15]	




























Symptomatics	 	 	 	 	 	 	
p	to	(𝑟"	-	1)	 25	 	 	 	 	
severe	cases,	
[68]	


























v	to	(𝑟"	-	1)	 18.5	 	 15.0	 22.0	 	
Wuhan,	CHN,	n=54,	
resolve=	death,	[82]	
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